{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:08Z","timestamp":1793214608794,"version":"4.5.0"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>The management of noninfectious uveitis (NIU) has involved the use of corticosteroids and immunomodulators (IMT). However, a certain subset of NIU patients does not respond to conventional IMT therapy, such as methotrexate and azathioprine. In these patients, biological IMT with specific targets is employed. One such example is the use of TNF-\u03b1 inhibitors, such as adalimumab and infliximab. These biologics target specific inflammatory cytokines, unlike the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. JAK-STAT inhibitors (JAKinibs) are classified as targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), which are small-molecule drugs that are chemically synthesized rather than biologically derived. In contrast to biologic DMARDs or bDMARDs, tsDMARDs are smaller molecules that are orally available, nonimmunogenic, and capable of crossing the cell membrane. JAKinibs can simultaneously block multiple cytokine-signalling pathways, such as those driven by IL-6, IL-12, IL-23 and IL-17, as they dampen Th1- and Th17-driven inflammation. This ability to target a broad range of inflammatory cytokines and immune pathways theoretically enables JAKinibs to be viable alternatives for the treatment of NIU resistant to conventional IMT and biologicals. JAK-STAT inhibitors, such as tofacitinib, baricitinib, upadacitinib, peficitinib, delgocitinib, and filgotinib have been FDA-approved for use in autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and inflammatory bowel disease. The available literature suggests the potential efficacy of these drugs in controlling uveitic inflammation; however, their use in NIU is still under investigation, with no randomized controlled trials providing Level I evidence.<\/jats:p>","DOI":"10.4103\/ijo.ijo_61_25","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:02:58Z","timestamp":1748430178000},"page":"807-815","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["JAK-STAT inhibitors in noninfectious uveitis \u2013 A review"],"prefix":"10.4103","volume":"73","author":[{"given":"Richa","family":"Pyare","sequence":"first","affiliation":[{"name":"Department of Retina and Uvea, Shroff Eye Centre, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawazish","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahana","family":"Sen","sequence":"additional","affiliation":[{"name":"Department of Uvea and Intraocular Inflammation, Sankara Nethralaya, College Road, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakshita","family":"Kene","sequence":"additional","affiliation":[{"name":"Department of Uvea and Intraocular Inflammation, Sankara Nethralaya, College Road, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Bagri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Janarthanan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Sri Ramachandra Institute of Higher Education and Research, Porur, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Chawla","sequence":"additional","affiliation":[{"name":"Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V","family":"Ramanan","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology Bristol Royal Hospital 55 for Children and Translational Health Sciences, University of Bristol, 56 Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthopratim","family":"Dutta Majumder","sequence":"additional","affiliation":[{"name":"Department of Uvea and Intraocular Inflammation, Sankara Nethralaya, College Road, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"R1-20260422","first-page":"3315","article-title":"Selective JAKinibs: Prospects in inflammatory and autoimmune diseases","author":"Virtanen","year":"2019","journal-title":"Bio Drugs Clin Immunother Biopharm Gene Ther"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1084\/jem.20071258","article-title":"Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category","volume":"205","author":"Luger","year":"2008","journal-title":"J Exp Med"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in Patients with Active Noninfectious Uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","article-title":"The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases","volume":"147","author":"Damsky","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.12.28","article-title":"Therapeutic effects of upadacitinib on experimental autoimmune uveitis: Insights from single-cell analysis","volume":"64","author":"Huang","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-20260422","first-page":"641","article-title":"Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells","volume":"26","author":"Bing","year":"2020","journal-title":"Mol Vis"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jneuroim.2005.07.021","article-title":"Induction of suppressors of cytokine signaling (SOCS) in the retina during experimental autoimmune uveitis (EAU): Potential neuroprotective role of SOCS proteins","volume":"168","author":"Takase","year":"2005","journal-title":"J Neuroimmunol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaut.2015.05.011","article-title":"Topical administration of a suppressor of cytokine signaling-1 (SOCS1) mimetic peptide inhibits ocular inflammation and mitigates ocular pathology during mouse uveitis","volume":"62","author":"He","year":"2015","journal-title":"J Autoimmun"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"2324400","DOI":"10.1155\/2021\/2324400","article-title":"Role of janus kinase (JAK) inhibitor in autoimmune ocular inflammation: A systematic review","volume":"2021","author":"Wen","year":"2021","journal-title":"J Immunol Res"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"107217","DOI":"10.1016\/j.phrs.2024.107217","article-title":"Small molecule drug discovery targeting the JAK-STAT pathway","volume":"204","author":"Lv","year":"2024","journal-title":"Pharmacol Res"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/1744666X.2023.2207823","article-title":"Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis","volume":"19","author":"Maccora","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","article-title":"Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: Study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)","volume":"22","author":"Ramanan","year":"2021","journal-title":"Trials"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2019","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","article-title":"Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis","volume":"27","author":"Bauermann","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"8294560","DOI":"10.1155\/2020\/8294560","article-title":"New potential weapons for refractory scleritis in the era of targeted therapy","volume":"2020","author":"Fabiani","year":"2020","journal-title":"Mediators Inflamm"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.4103\/ijo.IJO_534_20","article-title":"Tofacitinib in recalcitrant scleritis: First case report from India","volume":"68","author":"Pyare","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4103\/ijo.IJO_998_20","article-title":"Tofacitinib in Vogt-Koyanagi-Harada disease","volume":"68","author":"Dutta Majumder","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"225","DOI":"10.55563\/clinexprheumatol\/3gymd4","article-title":"Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis","volume":"39","author":"Sejournet","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"764067","DOI":"10.3389\/fmed.2021.764067","article-title":"Effectiveness of baricitinib in refractory seronegative rheumatoid arthritis and uveitis: A case report","volume":"8","author":"Kaneko","year":"2021","journal-title":"Front Med"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"784860","DOI":"10.3389\/fphar.2021.784860","article-title":"Case report: A promising treatment strategy for noninfectious uveitis","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/09273948.2022.2113805","article-title":"Tofacitinib in scleritis: A case series","volume":"32","author":"Pyare","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R25-20260422","first-page":"6201887","article-title":"A case of SAPHO syndrome complicated by uveitis with good response to both TNF inhibitor and JAKinib","volume":"2023","author":"Baisya","year":"2023","journal-title":"Case Rep Rheumatol"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"1759720X221093211","DOI":"10.1177\/1759720X221093211","article-title":"Clinical and immunological study of tofacitinib and baricitinib in refractory blau syndrome: Case report and literature review","volume":"14","author":"\u00c1lvarez-Reguera","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"e29189","DOI":"10.1097\/MD.0000000000029189","article-title":"Extended-release tofacitinib for refractory Beh\u00e7et disease: A case report","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R28-20260422","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1055\/a-1766-6739","article-title":"Intermediate uveitis in an HLA-B27-positive patient treated with upadacitinib","volume":"239","author":"Schneider","year":"2022","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R29-20260422","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4103\/ijo.IJO_789_22","article-title":"Tofacitinib in juvenile idiopathic arthritis-associated uveitis","volume":"2","author":"Babu","year":"2022","journal-title":"Indian Journal of Ophthalmology - Case Reports"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"109298","DOI":"10.1016\/j.clim.2023.109298","article-title":"Baricitinib for the treatment of refractory vascular Beh\u00e7et\u2019s disease","volume":"250","author":"Wang","year":"2023","journal-title":"Clin Immunol Orlando Fla"},{"key":"R31-20260422","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1080\/09273948.2023.2263557","article-title":"Successful remission with upadacitinib in two patients with anti-TNF-refractory macular edema associated with beh\u00e7et\u2019s uveitis","volume":"32","author":"Tao","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R32-20260422","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/09273948.2022.2069128","article-title":"Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: A case report","volume":"31","author":"Baquet-Walscheid","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R33-20260422","doi-asserted-by":"crossref","first-page":"367","DOI":"10.31138\/mjr.20230828.ti","article-title":"Tofacitinib in refractory scleritis: A case series","volume":"34","author":"Dey","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"R34-20260422","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1080\/09273948.2022.2145488","article-title":"Beneficial effect of upadacitinib in a refractory course of scleritis: A case report","volume":"32","author":"Baquet-Walscheid","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R35-20260422","doi-asserted-by":"crossref","first-page":"1439338","DOI":"10.3389\/fmed.2024.1439338","article-title":"Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: A prospective cohort study from the international AIDA network registries","volume":"11","author":"Vitale","year":"2024","journal-title":"Front Med"},{"key":"R36-20260422","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/09273948.2024.2323671","article-title":"Tofacitinib for refractory uveitis and scleritis in children: A case series","volume":"32","author":"Dutta Majumder","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R37-20260422","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT randomized clinical trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R38-20260422","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40744-018-0118-2","article-title":"Tofacitinib, an oral janus kinase inhibitor: Pooled efficacy and safety analyses in an australian rheumatoid arthritis population","volume":"5","author":"Hall","year":"2018","journal-title":"Rheumatol Ther"},{"key":"R39-20260422","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"R40-20260422","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"R41-20260422","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"R42-20260422","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"R43-20260422","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: A double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"R44-20260422","first-page":"7e162335","article-title":"Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease","author":"Liu","year":"2022","journal-title":"JCI Insight"},{"key":"R45-20260422","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12969-021-00634-x","article-title":"Tofacitinib effectiveness in Blau syndrome: A case series of Chinese paediatric patients","volume":"19","author":"Zhang","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"R46-20260422","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/annrheumdis-2019-215387","article-title":"Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib","volume":"78","author":"Levraut","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R47-20260422","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"R48-20260422","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R49-20260422","first-page":"187","article-title":"The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: A review of the literature","volume":"93","author":"Wang","year":"2020","journal-title":"Yale J Biol Med"},{"key":"R50-20260422","doi-asserted-by":"crossref","first-page":"1211240","DOI":"10.3389\/fimmu.2023.1211240","article-title":"Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome","volume":"14","author":"Ueki","year":"2023","journal-title":"Front Immunol"},{"key":"R51-20260422","doi-asserted-by":"crossref","first-page":"895765","DOI":"10.3389\/fimmu.2022.895765","article-title":"Potential benefits of TNF targeting therapy in blau syndrome, a NOD2-associated systemic autoinflammatory granulomatosis","volume":"13","author":"Matsuda","year":"2022","journal-title":"Front Immunol"},{"key":"R52-20260422","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"R53-20260422","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/ibd\/izac121","article-title":"Tofacitinib response in ulcerative colitis (TOUR): Early response after initiation of tofacitinib therapy in a real-world setting","volume":"29","author":"Long","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R54-20260422","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/2050640620935732","article-title":"Is tofacitinib a game-changing drug for ulcerative colitis?","volume":"8","author":"Magro","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"R55-20260422","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"R56-20260422","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14656566.2021.2006183","article-title":"Evaluating upadacitinib for the treatment of psoriatic arthritis","volume":"23","author":"Akpabio","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"R57-20260422","doi-asserted-by":"crossref","first-page":"e002236","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"},{"issue":"Suppl 1","key":"R58-20260422","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/annrheumdis-2023-eular.2394","article-title":"OP0061 development of extra-musculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis","volume":"82","author":"Poddubnyy","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R59-20260422","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R60-20260422","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R61-20260422","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"R63-20260422","first-page":"1046","article-title":"Characteristics of adverse event reporting of Xeljanz\/Xeljanz XR, olumiant, and rinvoq to the US food and drug administration","volume":"28","author":"Qian","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"R64-20260422","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/1744666X.2022.2039630","article-title":"Safety of JAK inhibitors: Focus on cardiovascular and thromboembolic events","volume":"18","author":"Atzeni","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"R65-20260422","doi-asserted-by":"crossref","first-page":"106359","DOI":"10.1016\/j.phrs.2022.106359","article-title":"Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted","volume":"183","author":"Benucci","year":"2022","journal-title":"Pharmacol Res"},{"key":"R66-20260422","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12348-023-00359-w","article-title":"Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib","volume":"13","author":"Manoharan","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R67-20260422","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R68-20260422","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: Clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"R69-20260422","doi-asserted-by":"crossref","first-page":"1759720X20936059","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: Focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R70-20260422","first-page":"1","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"R71-20260422","doi-asserted-by":"crossref","first-page":"115236","DOI":"10.1016\/j.bcp.2022.115236","article-title":"JAK-STAT signaling pathway in non-infectious uveitis","volume":"204","author":"Su","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"R72-20260422","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1007\/s10792-021-01851-9","article-title":"Protective effect of filgotinib in rat endotoxin-induced uveitis model","volume":"41","author":"Erda\u011f","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R76-20260422","article-title":"First patients enrolled in phase 3 CLARITY trial evaluating brepocitinib in non-anterior non-infectious uveitis","author":"Harp","year":"2024","journal-title":"Ophthalmology Times"},{"key":"R77-20260422","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3390\/microorganisms9071481","article-title":"Ruxolitinib alleviates uveitis caused by salmonella typhimurium endotoxin","volume":"9","author":"Du","year":"2021","journal-title":"Microorganisms"},{"key":"R78-20260422","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/ajd.14248","article-title":"Janus kinase inhibitor abrocitinib as an off-Label treatment for tattoo granuloma with uveitis (TAGU)","volume":"65","author":"Yang","year":"2024","journal-title":"Australas J Dermatol"},{"key":"R79-20260422","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/psp4.13104","article-title":"Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis","volume":"13","author":"Chang","year":"2024","journal-title":"CPT Pharmacomet Syst Pharmacol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_61_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:55:15Z","timestamp":1786647315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_61_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_61_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"2025-01-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}